Core Viewpoint - A class action lawsuit has been filed against Freeport-McMoRan Inc. and certain senior executives for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Arizona, captioned Reed v. Freeport-McMoRan Inc., et al., No. 2:25-cv-04243 [3]. - Investors have until January 12, 2026, to request to be appointed to lead the case [3]. Group 2: Company Operations and Safety Claims - Freeport-McMoRan operates the Grasberg Copper and Gold Mine in Indonesia, where it has been accused of overstating its commitment to safety while conducting unsafe mining practices [4][5]. - The company had previously promoted its safety procedures, including the use of data and technology to prevent fatal incidents [4]. Group 3: Stock Price Impact - On September 9, 2025, Freeport's stock dropped by $2.77 per share (over 5.9%) following a press release about suspended mining operations due to a landslide [6]. - Following an update on September 24, 2025, indicating two fatalities and a projected 4% and 6% decrease in copper and gold sales, the stock fell by $7.69 per share (almost 17%) [7]. - On September 25, 2025, reports of strained relations with the Indonesian government led to an additional drop of $2.33 per share (over 6%) [8]. - An Indonesian news report on September 28, 2025, suggested the incident was preventable, further impacting investor confidence [9].

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc for allegedly making false statements regarding product demand and inventory levels during the specified Class Period, leading to significant stock price decline after the truth was revealed [1][3]. Company Overview - James Hardie Industries plc is a multinational building materials company based in Dublin, Ireland, specializing in fiber cement and related construction products [2]. Legal Proceedings - The lawsuit is on behalf of investors who purchased James Hardie securities between May 20, 2025, and August 18, 2025, with a deadline for potential lead plaintiff representatives set for December 23, 2025 [2][4]. - The complaint alleges that despite internal data indicating reduced inventory levels as early as April 2025, the company misled investors by claiming strong demand and normal inventory levels [3]. Financial Impact - On August 19, 2025, James Hardie disclosed a 12% decline in segment sales and warned of ongoing weakness, resulting in a stock price drop of over 34% in a single trading day [3].

Core Points - Kaskela Law LLC has initiated an investigation into Priority Technology Holdings, Inc. (NASDAQ: PRTH) on behalf of long-term shareholders [1] - The investigation aims to determine if Priority and its officers and directors violated securities laws or breached fiduciary duties related to recent corporate actions [2] Company Performance - Since February 2025, Priority's stock price has dropped from over $12.00 per share to below $6.00 per share, representing a decline of over 50% [2]

Core Viewpoint - Ademi & Fruchter LLP is investigating potential securities fraud claims against DexCom, Inc. due to inaccurate statements regarding its business operations and the quality of its products [1][2]. Group 1: Investigation Details - The investigation centers on DexCom's claims about its G7 blood glucose monitor, asserting it was of high quality and manufactured with FDA-approved materials [2]. - Reports indicate that DexCom altered the sensor membrane coating material from a third-party supplier to an in-house formulation without notifying the FDA or investors, which deviated from the FDA-approved formulation [2]. - The investigation period spans from January 8, 2024, to September 17, 2025 [2].

Nov 24, 2025 9:20 AM Eastern Standard Time Freeport McMoRan Inc. (FCX) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - Robbins Geller Rudman & Dowd LLP Share SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Freeport-McMoRan Inc. (NYSE: FCX) publicly traded securities between February 15, 2022 and September 24, 2025, inclusive (the "Class Period†), have until January 12, 2026 to seek appointment ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Primo Brands Corporation regarding a class action lawsuit due to alleged false statements and supply disruptions following the merger with BlueTriton Brands [1][2]. Group 1: Allegations and Issues - The class action alleges that the defendants made false statements and concealed poor integration tracking of the merger between Primo Water and BlueTriton Brands, citing technology and service issues as contributing factors [2]. - Contrary to the defendants' claims of a "flawless" execution, significant supply disruptions were reported, which negatively impacted customers and the financial results of Primo Brands [2]. Group 2: Class Action Details - The class period for the lawsuit is from June 17, 2024, to November 6, 2025, and shareholders are encouraged to register for participation [2][3]. - The deadline for shareholders to seek lead plaintiff status is January 12, 2026, with no cost or obligation to participate in the case [3]. Group 3: Firm's Mission and Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of James Hardie Industries plc regarding a class action lawsuit due to alleged false statements and concealed adverse facts about the company's North America segment [1][2]. Summary by Relevant Sections Allegations - The complaint alleges that James Hardie's North America segment faced deteriorating primary consumer demand and growth [1]. - It is claimed that overstocking was the main driver of growth in the North America segment during the class period, rather than genuine consumer demand [1]. - Excessive inventory at James Hardie's North America distributors is cited as a consequence of these issues [1]. Class Period and Registration - The class period for the allegations is from May 20, 2025, to August 18, 2025 [1]. - Shareholders are encouraged to register for the class action by December 23, 2025, to potentially be appointed as lead plaintiffs [2]. Firm's Mission - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices [3]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that led to artificial inflation of stock prices [3].

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics for allegedly misleading investors regarding the efficacy of its drug candidate, sonelokimab (SLK), which reportedly failed to meet clinical benchmarks [1][3][4]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotech firm based in Zug, Switzerland, focusing on next-generation immunotherapies [2]. Legal Proceedings - The lawsuit is on behalf of investors who purchased MoonLake shares between March 10, 2024, and September 29, 2025, with a deadline of December 15, 2025, for investors to seek lead plaintiff status [1][2]. Drug Candidate Details - MoonLake promoted SLK as a breakthrough treatment due to its Nanobody structure but allegedly failed to disclose that it targets the same molecules as BIMZELX, an FDA-approved monoclonal antibody, indicating it was not clinically superior [3]. Trial Results and Market Impact - On September 28, 2025, MoonLake disclosed that SLK did not meet efficacy benchmarks in Phase 3 trials, leading to a significant stock price decline of $55.75 per share, nearly 90%, in one trading session [4].

Core Viewpoint - Stride, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims of misleading statements and non-compliance with legal requirements during the class period from October 22, 2024, to October 28, 2025 [1][3]. Allegations Against Stride - The lawsuit alleges that Stride inflated enrollment numbers by retaining "ghost students" and cut staffing costs by overloading teachers beyond statutory limits [3]. - Stride is accused of ignoring compliance requirements, including background checks and licensure laws, and failing to provide federally mandated special education services [3]. - The company allegedly suppressed whistleblowers who reported financial directives aimed at preserving profit margins by delaying hiring and denying services [3]. - Stride reportedly lost existing and potential enrollments due to these practices [3]. Impact of Legal Issues - A complaint filed by the Gallup-McKinley County Schools Board of Education against Stride on September 14, 2025, led to a nearly 12% drop in Stride's stock price [4]. - Following an announcement on October 28, 2025, regarding "poor customer experience" leading to higher withdrawal rates and an estimated loss of 10,000-15,000 enrollments, Stride's stock price fell more than 54% [5]. Class Action Process - Investors who purchased Stride securities during the class period can seek appointment as lead plaintiff in the lawsuit, representing the interests of the class [6]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect the ability to share in any potential recovery [6]. About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has been recognized for securing significant monetary relief for investors, including the largest recovery in history of $7.2 billion in the Enron case [7].

Core Viewpoint - CarMax, Inc. is facing a class action lawsuit for securities fraud following a significant stock drop of approximately 20% after disappointing financial results and the unexpected departure of its CEO [1][6][7]. Financial Performance - CarMax reported a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units for the second quarter of fiscal year 2026 [6]. - The company's net income for the second quarter was approximately $95.4 million, down from $132.8 million in the previous year [6]. - The stock price fell from $57.05 per share on September 24, 2025, to $45.60 per share on September 25, 2025, a drop of $11.45 per share or roughly 20% [7]. Legal Issues - A class action lawsuit has been filed against CarMax and certain senior executives under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - The lawsuit claims that CarMax misrepresented the demand for its cars, which was allegedly boosted by short-term factors such as U.S. tariffs [4]. - The unexpected departure of CEO Bill Nash on November 6, 2025, is also under investigation regarding the company's assessment of its car loan portfolio [5].